by Ellie Lampton | Aug 6, 2026
New JAMIA Open paper describes how health systems, artificial intelligence, and continuously updated clinical data can transform routine care into living evidence BELLEVUE, Wash., August 6, 2026—Truveta announced the publication of a new peer-reviewed paper in JAMIA...
by Ellie Lampton | Jul 29, 2026
Published in JCO Clinical Cancer Informatics, new Truveta research demonstrates scalable, high-precision extraction of critical cancer staging information BELLEVUE, Wash.—July 28, 2026—Truveta recently published a peer-reviewed study in JCO Clinical Cancer Informatics...
by Ellie Lampton | Jul 21, 2026
Large multi-system study using target trial emulation found consistent associations across patients with alcohol use disorder and either type 2 diabetes or obesity BELLEVUE, Wash.—July 21, 2026—Researchers from Truveta, Johns Hopkins Bloomberg School of Public Health,...
by Ellie Lampton | Jun 29, 2026
Analysis of nearly 68,000 patients finds biosimilar adoption increased following formulary changes; however, more than 1 in 7 patients switch back to Humira BELLEVUE, Wash.—June 29, 2026—Researchers from Truveta have found that adoption of adalimumab biosimilars...
by Ellie Lampton | Jun 18, 2026
Analysis of nearly 154,000 adults identifies key factors associated with shingles vaccine uptake and completion BELLEVUE, Wash.—June 18, 2026—Researchers from Truveta have found that uptake of the shingles vaccine Shingrix has increased substantially among adults...
